0

Polycystic Ovary Syndrome (PCOS) Drugs Market by Drug Class and Geography - Forecast and Analysis 2021-2025

  • Published: Feb 2021
  • Pages: 120
  • SKU: IRTNTR70204
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The polycystic ovary syndrome (PCOS) drugs market size has the potential to grow by USD  711.14 million during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 4.80%. 

This report provides a detailed analysis of the market by drug class (insulin sensitizing agents, oral contraceptives, aromatase inhibitors, and other drug classes), geography (North America, Europe, Asia, and ROW), and key vendors. 

Market Overview

Polycystic-Ovary-Syndrome-(PCOS)-Drugs-Market-Market-Size-2020-2025

Browse TOC and LoE with selected illustrations and example pages of Polycystic Ovary Syndrome (PCOS) Drugs Market

 Request a FREE sample now!

Market Competitive Analysis

The report analyzes the market’s competitive landscape and offers information on several market vendors, including: 

 

  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • Ferring Pharmaceuticals AS
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

 

The polycystic ovary syndrome (PCOS) drugs market is fragmented and the vendors are deploying growth strategies such as R&D to compete in the market. Click here to uncover other successful business strategies deployed by the vendors. 

The market players also significantly leverage external market drivers such as increasing prevalence of chronic diseases to achieve growth opportunities. However, factors such as lack of approved drugs will challenge the growth of the market participants. To make the most of the opportunities and recover from post COVID19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Download a free sample of the polycystic ovary syndrome (PCOS) drugs market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

This polycystic ovary syndrome (PCOS) drugs market analysis report also provides detailed information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities. 

Polycystic Ovary Syndrome (PCOS) Drugs Market: Key Drivers and Trends

  • The increasing prevalence of chronic diseases is one of the key factors driving the growth of the market during the forecast period.
  • Although the main cause of PCOS is still undetermined, high levels of male hormones are likely to prevent the ovaries from producing female hormones and making eggs normally.
  • Diabetes is one of the most common chronic diseases. Patients with diabetes may have several clinical conditions, including overweight, hypertension, and obesity, which are risk factors for PCOS.
  • The rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of women having PCOS, which, in turn, will drive the growth of the global PCOS drugs market during the forecast period.
  • Increasing rate of unplanned pregnancies and unnecessary abortions is one of the key trends driving the growth of the market during the forecast period.
  • Unplanned pregnancies are one of the most pressing public health problems and a significant issue for global reproductive health.
  • The rising prevalence of unnecessary abortions is also likely to increase the demand for PCOS drugs, resulting in the growth of the market.
  • Women suffering from PCOS are highly prone to complications during pregnancies. Hence, a large number of unnecessary pregnancies and abortions will drive the need for more effective PCOS drugs to lower the rate of unnecessary pregnancies and abortions and help in planning a family only when a couple is ready to have a child.

 

Grab your Free Sample now to unlock further information on other key market drivers

Polycystic Ovary Syndrome (PCOS) Drugs Market: Segmentation by Geography

Polycystic-Ovary-Syndrome-(PCOS)-Drugs-Market-Market-Share-by-Region-2020-2025

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market’s growth will originate from North America during the forecast period. The US is one of the key markets for polycystic ovary syndrome (PCOS) drugs in North America. Market growth in this region will be slower than the growth of the market in Asia.

The presence of well-established pharmaceutical giants in the region and huge investments from governments for patient assistance and R&D activities are the prime factors that will facilitate the polycystic ovary syndrome (PCOS) drugs market growth in North America over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report. 

Polycystic Ovary Syndrome (PCOS) Drugs Market: Segmentation by Drug Class

Polycystic-Ovary-Syndrome-(PCOS)-Drugs-Market-Market-Share-by-Drug Class-2020-2025

Request for a FREE sample and Get more information on the market contribution of various segments

Insulin sensitizing agents are recognized as the therapy of choice for the treatment of PCOS since hyperinsulinemia and insulin resistance are considered as vital pathogenetic factors for the indication. Since a majority of obese women who suffer from PCOS and more than half of the patients who are within their ideal weight are insulin-resistant and hence present some degree of hyperinsulinemia, the use of insulin-sensitizing agents is prescribed in most patients with PCOS. Hence, the market segment will exhibit a fast growth rate during the forecast period.

Fetch actionable market insights on post COVID-19 impact on each segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the polycystic ovary syndrome (PCOS) drugs market size.

 

Event-Tickets-Market-Report

Request for a FREE sample

Polycystic Ovary Syndrome (PCOS) Drugs Market: Key Highlights of the Report for 2021-2025

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive polycystic ovary syndrome (PCOS) drugs market growth during the next five years
  • Precise estimation of the polycystic ovary syndrome (PCOS) drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the polycystic ovary syndrome (PCOS) drugs industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of polycystic ovary syndrome (PCOS) drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Polycystic Ovary Syndrome (PCOS) Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 5%

Market growth 2021-2025

$ 711.14 million

Market structure

Fragmented

YoY growth (%)

4.41

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 35%

Key consumer countries

US, Germany, UK, Japan, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Market characteristics
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025

    Five Forces Analysis

    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Drug Class

    • Market segments
    • Comparison by drug class
    • Insulin sensitizing agents - Market size and forecast 2020-2025
    • Oral contraceptives - Market size and forecast 2020-2025
    • Aromatase inhibitors - Market size and forecast 2020-2025
    • Other drug classes - Market size and forecast 2020-2025
    • Market opportunity by drug class

    Customer landscape

    • Customer landscape

    Geographic Landscape

    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends

    Vendor Landscape

    • Competitive scenario
    • Vendor landscape
    • Landscape disruption

    Vendor Analysis

    • Vendors covered
    • Market positioning of vendors
    • AbbVie Inc.
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • Cipla Inc.
    • Ferring Pharmaceuticals AS
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

    Appendix

    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

    Research Framework

    Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

    TechnavioINFORMATION SOURCES

    Primary sources

    • Manufacturers and suppliers
    • Channel partners
    • Industry experts
    • Strategic decision makers

    Secondary sources

    • Industry journals and periodicals
    • Government data
    • Financial reports of key industry players
    • Historical data
    • Press releases
    Technavio

    TechnavioDATA ANALYSIS

    Data Synthesis

    • Collation of data
    • Estimation of key figures
    • Analysis of derived insights

    Data Validation

    • Triangulation with data models
    • Reference against proprietary databases
    • Corroboration with industry experts
    Technavio

    TechnavioREPORT WRITING

    Qualitative

    • Market drivers
    • Market challenges
    • Market trends
    • Five forces analysis

    Quantitative

    • Market size and forecast
    • Market segmentation
    • Geographical insights
    • Competitive landscape
    Interested in this report?
    Get your FREE sample now!
    The polycystic ovary syndrome (pcos) drugs market growth will increase by $711.14 million during 2020-2025.
    The polycystic ovary syndrome (pcos) drugs market is expected to grow at a CAGR of 4.80% during 2020-2025.
    Technavio has segmented the polycystic ovary syndrome (pcos) drugs market by other1 (Insulin sensitizing agents, Oral contraceptives, Aromatase inhibitors, and Other drug classes) and geographic (North America, Europe, Asia, and ROW).
    AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. are a few of the key vendors in the polycystic ovary syndrome (pcos) drugs market.
    North America will register the highest growth rate of 34.75% among the other regions. Therefore, the polycystic ovary syndrome (pcos) drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
    The key factors driving the polycystic ovary syndrome (pcos) drugs market growth are:
    • Increasing prevalence of chronic diseases
    The polycystic ovary syndrome (pcos) drugs market vendors should focus on grabbing business opportunities from the insulin sensitizing agents segment as it accounted for the largest market share in the base year.
    Safe and Secure SSL Encrypted
    Technavio

    Single User:

    2500 USD

    Technavio Get the report (PDF) sent to your email within minutes.

    Subscribe & Save

    Get lifetime access to our
    Technavio Insights

    Want to customize this report?

    This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

    We offer $1000 worth of FREE customization at the time of purchase
    Technavio
    Enquire Before Buying
    1. Home
    2. Health Care
    3. Published Report
    17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>